Tumor Protein P53 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| TP53 |
|---|
| Protein Name | Tumor Protein P53 (Cellular Tumor Antigen P53) |
|---|
| Gene | TP53 |
|---|
| UniProt ID | P04637 |
|---|
| PDB IDs | 1TUP, 1H26, 2OCJ |
|---|
| Molecular Weight | 43.7 kDa |
|---|
| Subcellular Localization | Nucleus (transcription factor) |
|---|
| Protein Family | P53 Family (Trp53) |
|---|
P53 is a transcription factor containing several distinct domains:
- N-terminal Transactivation Domain (TAD): Contains two subdomains (TAD1, TAD2) for transcriptional activation
- Proline-Rich Domain (PRD): Mediates protein-protein interactions
- Central DNA-Binding Domain (DBD): Binds to p53 response elements (p53 RE) as a tetramer
- Oligomerization Domain (OD): Forms tetramers essential for DNA binding
- C-terminal Regulatory Domain (CTD): Modulates DNA binding and contains nuclear localization signals
The protein functions as a homotetramer, with each monomer containing 393 amino acids.
P53 is the "guardian of the genome" and functions as a critical tumor suppressor:
- Cell Cycle Arrest: Activates p21 to halt cell cycle progression
- Apoptosis: Induces pro-apoptotic genes (BAX, PUMA, NOXA)
- DNA Repair: Upregulates DNA repair proteins
- Senescence: Induces cellular senescence programs
- Metabolism: Modulates glycolysis and oxidative phosphorylation
- Stem Cell Regulation: Maintains stem cell populations
P53 expression is ubiquitous but regulated:
- Brain: Neurons and glia express p53 at baseline levels
- Neurons: Higher expression in hippocampal and cortical neurons
- Glia: Inducible expression in astrocytes and microglia
- Development: Low expression during development, increases with stress
P53 plays complex roles in neurodegeneration:
- Elevated in AD brains
- Mediates Aβ-induced neuronal apoptosis
- Links amyloid pathology to neuronal death
- DNA damage accumulation activates p53
- Involved in dopaminergic neuron apoptosis
- Mediates mitochondrial dysfunction pathways
- Activated by oxidative stress
-PARK genes interact with p53 pathways
- Motor neuron vulnerability associated with p53
- Mutant SOD1 induces p53 activation
- Therapeutic targeting under investigation
- Mutant huntingtin activates p53
- Contributes to striatal neuron death
- DNA damage response dysregulation
- Major mediator of ischemic neuronal death
- Therapeutic target for neuroprotection
- P53 Inhibitors: For acute neuroprotection (pifithrin-α)
- Mdm2 Inhibitors: Activate p53 for anti-cancer, potential for neurodegeneration
- Gene Therapy: Limited by dual nature of p53
- Chronic p53 activation may be detrimental
- Acute vs. chronic targeting differs
- Balancing pro-survival and pro-death functions
- Understanding cell-type specific p53 functions
- Developing brain-penetrant p53 modulators
- Biomarker development for p53 activation status
- Targeting p53 in specific neurodegenerative contexts
The study of Tumor Protein P53 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Vousden KH, Lu X (2002). Live or let die: the cell's response to p53. Cell. PMID:12426774
- Lanni C, et al. (2012). p53 in the central nervous system. Cell Death and Differentiation. PMID:22858545
- Simao G, et al. (2021). p53 in neurodegeneration. Frontiers in Cellular Neuroscience. PMID:34539361
- Tedesco E, et al. (2023). p53 and Alzheimer's disease: A complex interplay. Ageing Research Reviews. PMID:36940281
- Wadhwa R, et al. (2020). Targeting p53 as a therapeutic strategy for neurodegeneration. Pharmacology & Therapeutics. PMID:32739320